Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Avidity Biosciences' Depreciation & Amortization (CF) rose 5714.29% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 3103.71%. This contributed to the annual value of $2.8 million for FY2024, which is 3326.99% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Depreciation & Amortization (CF) is $1.1 million, which was up 5714.29% from $800000.0 recorded in Q2 2025.
  • Avidity Biosciences' 5-year Depreciation & Amortization (CF) high stood at $1.1 million for Q3 2025, and its period low was $100000.0 during Q2 2021.
  • For the 5-year period, Avidity Biosciences' Depreciation & Amortization (CF) averaged around $506736.8, with its median value being $500000.0 (2023).
  • As far as peak fluctuations go, Avidity Biosciences' Depreciation & Amortization (CF) changed by 0.0% in 2021, and later skyrocketed by 20000.0% in 2022.
  • Over the past 5 years, Avidity Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $208000.0 in 2021, then surged by 89.42% to $394000.0 in 2022, then soared by 52.54% to $601000.0 in 2023, then rose by 26.79% to $762000.0 in 2024, then surged by 44.36% to $1.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.1 million for Q3 2025, versus $800000.0 for Q2 2025 and $800000.0 for Q1 2025.